Publication
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Journal Paper/Review - Nov 1, 2020
Mark Michael, Früh Martin, Biaggi-Rudolf Christine, Weindler Susanne, Baudoux Nathalie, Schwitter Michael, Wannesson Luciano, Jörger Markus, Metaxas Yannis, Schneider Martina, Friedlaender Alex, Burmeister Henning, Janthur Wolf-Dieter, Rothschild Sacha I, Pless Miklos, Addeo Alfredo, Eboulet Eric Innocents, Froesch Patrizia, Swiss Group for Clinical Cancer Research (SAKK)
Mark, Michael
13
0
Froesch, Patrizia
8
0
Eboulet, Eric Innocents
3
0
Addeo, Alfredo
5
0
Pless, Miklos
31
1
Rothschild, Sacha I
21
0
Janthur, Wolf-Dieter
3
0
Burmeister, Henning
1
0
Friedlaender, Alex
2
0
Schneider, Martina
3
0
Metaxas, Yannis
5
0
Jörger, Markus
chief of serviceMedizinische Onkologie und Hämatologie · Dept. I
175
42
Wannesson, Luciano
7
0
Schwitter, Michael
3
0
Baudoux, Nathalie
1
0
Weindler, Susanne
Medizinische Onkologie und Hämatologie · Dept. I
1
3
Biaggi-Rudolf, Christine
2
0
Früh, Martin
Medizinische Onkologie und Hämatologie · Dept. I
123
37
Swiss Group for Clinical Cancer Research (SAKK),
31
0